Erdogan-Trinkaus Ipek reported option exercise involving 3,500 derivative units of Eton Pharmaceuticals, Inc. at $0.00 for $0 on Nov 10, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Commercial Officer
Chief Commercial Officer
Filed Nov 12, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
3,500Employee Stock Option
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
37,155Direct
Trade date
Nov 10, 2026Option exercise
Filed
Nov 12, 2026, 4:45 PM ET2-day reporting delay
Accession
0001437749-26-036605Code M · Transaction 399226
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 10, 2026Option exercise3,500$15.47$54,145Trade 399223
Nov 10, 2026Sell2,340$67.18−$157,198.16Trade 399224
Nov 10, 2026Sell1,160$67.88−$78,739.06Trade 399225
4 transaction rows in this filing. Joint filers share the same rows.

ETON price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ETON · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −10%1w ago −17%1d ago −17%
Returns since7d30d90d180d1y

Footnotes in full

F1: The shares subject to the option vest in 48 equal monthly installments from the date of grant (1-12-2026) until fully vested and exercisable on January 12, 2030. F2: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F3: The shares were sold in multiple trades at prices ranging from $66.645 to $67.62. The price reported above reflects the weighted average sales price. F4: The shares were sold in multiple trades at prices ranging from $67.6825 to $68.075. The price reported above reflects the weighted average sales price.